Articles tagged with Drug Studies
Researchers have identified a repurposed drug that can 'wake up' damaged peripheral nerves, speeding up repair and functional recovery after injury. Daily treatment with 4-aminopyridine accelerates myelin damage repair and improves nerve function.
A new study examines the effectiveness of duloxetine for stress urinary incontinence and finds that while it lessens incontinence frequency, adverse effects and suicidality are more common with duloxetine compared to a placebo.
A new study found that combining rivaroxaban with single or dual anti-platelet therapy reduces clinically significant bleeding in patients with atrial fibrillation who undergo stenting procedures. The treatment strategy also lowers risks of rehospitalization and death from all causes.
Researchers used mass spectrometry to detect molecules on phones and skin, creating personalized lifestyle profiles with diet, medication, beauty product usage, health status, and location information. The study has potential applications in crime scene investigations, airport screening, and environmental exposure studies.
A study of nearly 2,400 elderly heart attack survivors found that only 9.8% filled prescription medications for smoking cessation within 90 days after discharge. Factors such as age and previous heart procedures made it less likely for patients to use these medications.
A 10-year precision trial involving 24,081 patients in 13 countries investigated the cardiovascular safety of widely used nonsteroidal anti-inflammatory drugs and COX-2-specific inhibitors. The trial found that celecoxib shares similar cardiovascular toxicity with rofecoxib, leading to increased nuance in analgesic recommendations for ...
A new study by Intermountain Medical Center Heart Institute found that two different blood clot prevention medications are just as safe and effective for patients undergoing percutaneous coronary intervention. The risk of major bleeding after 30 days was low and not significantly different between the two treatment methods.
Studies in the US and Denmark show that older adults are undertrained in CPR, with only 18% reporting current training. Higher education level and household income are linked to increased likelihood of CPR training, but there is a steep drop-off after age 50. The elderly often cite lack of knowledge and fear as barriers to performing CPR.
Two studies show that schools implementing asthma care programs and vaccinating children with asthma against the flu can significantly improve attendance rates. A total of 90% of students were able to return to class after receiving treatment, compared to 11% without access to these services.
Research found promising initial evidence that specific neuroimaging markers can help predict the response to psychotherapy in patients with depression or anxiety. Neuroimaging markers such as activity in the amygdala, anterior insula, and anterior cingulate cortex may indicate which patients are more likely to benefit from psychotherapy.
A clinical trial is testing a new device that could ease heart failure symptoms in patients with preserved ejection fraction. The Corvia Medical InterAtrial Shunt Device makes a small hole to redistribute blood and reduce pressure, allowing patients like Jimmy McMillan to breathe better and live more comfortably.
Immunotherapy has shown modest control of HIV and identified pre-existing drug resistance as an important barrier to antibody-based treatments. The study used broadly neutralizing HIV antibodies, but suppression did not surpass 8 weeks in most participants.
A large clinical trial found that a combination of propofol and ketamine was as effective as propofol alone for sedating adults in emergency departments. The study debunked concerns about ketamine causing adverse psychological reactions, revealing similar outcomes and high patient satisfaction rates.
A new clinical trial at UTHealth aims to develop more effective treatment strategies tailored to individual responses for patients overcoming cocaine addiction. The study combines motivational incentives with mindfulness skills training to boost abstinence rates and improve patient outcomes.
The first of five clinical trials for an investigational Zika vaccine began at the Walter Reed Army Institute of Research, testing the safety and ability of the ZPIV vaccine to generate an immune system response. The Phase 1 trial aims to enroll 75 people aged 18-49 with no prior flavivirus infection.
The SWOG and The Hope Foundation's efforts are paying off, with 13 NCTN trials now open to veterans at participating medical centers. Veterans like Jerry Valentino have successfully enrolled in trials, responding well to cutting-edge treatments.
Researchers developed a potent and well-tolerated BACE1 inhibitor, verubecestat, which safely reduced toxic β-amyloid levels in AD patients. The drug has shown promise in clearing amyloid plaques and is currently advancing to phase 3 trials.
Researchers at the University of Miami are investigating a combination of CBD and NMDA antagonist to reduce brain inflammation and symptoms associated with concussion. The goal is to develop a clinically proven medication to treat cognitive and emotional consequences of single and repetitive brain injuries.
The BIO-RESORT trial found that two thin-strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents were non-inferior to a durable polymer zotarolimus-eluting stent in treating coronary artery disease. Patients with acute coronary syndromes showed excellent one-year clinical outcomes.
The BIONICS trial found that the ridaforolimus-eluting stent was non-inferior to the zotarolimus-eluting stent in terms of target lesion failure rates and had a low rate of stent thrombosis. The study, which enrolled over 1,900 patients, showed similar outcomes for cardiac death, TV-MI, and ID-TLR.
A University of Pittsburgh-developed program successfully increases vaccination rates in adult patients seen at primary care offices. Practices participating in the 4 Pillars Practice Transformation Program had nearly three times the increase in Tdap vaccine uptake compared to non-participating offices.
A study found that nearly half of cancer patients expect their tumors to shrink after participating in phase I clinical trials, despite the realistic response rate being much lower. The results highlight the need to improve patient information and consent forms.
Researchers pinpoint unique brain region for placebo response in pain relief, enabling targeted pain therapy and more accurate clinical trials. This finding could lead to personalized medicine for the 100 million Americans with chronic pain.
A systematic review of 14 studies found that mobile app users with type 2 diabetes experienced a reduction in average blood glucose levels, with an approximate 0.5% decrease in HbA1c. Younger patients reported more benefits from using apps.
Researchers found that tranexamic acid effectively reduces bleeding in patients undergoing heart surgery. Additionally, studies suggest witholding common blood pressure medications before surgery may improve patient recovery and mortality rates.
A recent study found that Medicaid policies requiring tobacco-cessation counseling actually decrease the use of anti-smoking medications among smokers, with a one-quarter to one-third reduction. This is due to barriers erected for smokers who want to quit.
A review of medical literature found only 92 gold-standard clinical trials on immediate cardiac arrest treatment over the last 20 years, despite 535,000 annual cases in the US. The study highlights a significant lack of research on post-arrest care and long-term survival outcomes.
A study published in The New England Journal of Medicine found that commonly prescribed preventive medicines for pediatric migraines are no more effective than a sugar pill. Instead, a multi-disciplinary approach and the expectation of response may be key to preventing headaches in children and teens.
A study published in JAMA Dermatology found that patients given electronic prescriptions were more likely to fill and pick up their dermatological medications. Rates of primary nonadherence decreased in older patients but increased in those over 70.
A randomized controlled trial found no significant differences between ultrasound and sham treatment for tibial fracture healing or functional recovery. The study suggests abandoning low-intensity pulsed ultrasonography (LIPUS) as an ineffective treatment option for patients with tibial fractures.
A team of researchers from Wayne State University will test a technology-based intervention to improve medication adherence among African American emerging adults with moderate to severe persistent asthma. The goal is to enhance illness management and health outcomes at a low cost.
The Critical Path Institute's CPTR initiative and the WHO Global TB Programme partnered to develop quantitative analyses of TB-PACTS database data. The collaboration, called TB-ReFLECT, will extract key lessons and package them as tools for future trial design.
Researchers found that medication adherence significantly impacts long-term survival rates for heart patients undergoing bypass surgery and stenting. Patients who adhered to prescribed medication therapy had a higher event-free survival rate compared to non-compliant patients.
A simple instruction sheet significantly increases patient compliance with preoperative medication instructions, reducing errors by 40%. The intervention has been found to improve patient safety and comfort, while also limiting surgical cancellations.
Harvard researchers develop a 3D-printed heart-on-a-chip with integrated sensors, enabling easy data collection and customization. The device mimics the structure and function of native tissue, opening new avenues for in vitro tissue engineering and drug screening research.
The National Alzheimer Project Act lacks a strategy to determine the clinical benefit of investigational drugs, potentially leading to exploitation by private interests. Authors propose three key questions to address this issue: slowing cognitive decline, lengthening disease stages, and delaying death.
Researchers used genomic testing and data analysis to predict patient response to psoriasis treatment. The approach identified gene-expression profiles that can be used to forecast treatment success with over 95% accuracy.
A placebo-controlled trial found that high-dose folinic acid significantly improved verbal communication skills in children with autism. The treatment also showed promise for predicting response to treatment through specific biomarkers.
A new study by Yale School of Medicine researchers found that financial barriers to healthcare services and medication significantly worsened quality of life, depressive symptoms, and stress among young adults with myocardial infarction. Despite the expansion of insurance coverage, young adults still struggle to access affordable care.
A large HIV prevention trial found that women experiencing intimate partner violence were less likely to use a vaginal ring, with improved adherence after disclosure. Counseling and support can help these women adhere to the ring, improving their protection against HIV.
Limited awareness and physician concerns about patient reactions contribute to the continuation of potentially inappropriate medications (PIMs) at the end of life. Emphasizing the benefits of stopping PIMs, such as reduced pill burden, may increase their discontinuation.
A Phase 2 study of a novel colonoscopy prep found it to be at least as effective and safe as existing products, while offering higher levels of patient satisfaction and preference. The investigational treatment allows patients to eat solid food bars and drink palatable beverages, leading to nearly four times more recommendations.
A UA-led study found selenium supplementation significantly increased the risk of developing type 2 diabetes, casting doubt on its effectiveness for preventing colorectal cancer. The study suggests a reevaluation of selenium supplements' use due to this potential adverse effect.
Researchers at Scripps Research Institute have identified a new therapeutic target for obesity and type 2 diabetes, IP6K1. The protein promotes fat accumulation by slowing down the breakdown of fat and enhancing weight gain in animal models.
A pivotal Phase III clinical study is exploring the impact of vericiguat on patients with chronic heart failure with reduced ejection fraction. The trial aims to assess whether adding vericiguat to standard treatment can improve heart and vascular function, reducing the risk of cardiovascular death or hospitalization.
A randomized controlled trial found ZMapp to be safe and well-tolerated, with a 40% lower risk of death for those who received the treatment. However, the trial was conducted during a public health emergency and enrolled too few participants to determine definitively whether ZMapp is superior to standard care alone.
A new clinical trial confirms that general practitioner-prescribed treatments can significantly help women with heavy periods. The trial found that most women avoid surgical interventions and experience similar improvement in period heaviness regardless of treatment type.
A recent study by University of Tennessee professors found that most consumers skim over risk warnings on drug websites, ignoring important information about potential side effects. The researchers suggest presenting risks before benefits and highlighting unique risks with graphics to increase attention.
Researchers found that male rats with normal testosterone levels had stronger ACLs than those without it. The study suggests a link between testosterone and ACL injuries, which could lead to new techniques for identifying athletes at high risk of injury.
PharmaMar's Phase 2 study shows significant reduction in tumor size and improved survival rates for patients with BRCA 1/2 metastatic breast cancer. The trial achieved an overall response rate of 41% with a 61% response rate in the BRCA 2 subgroup.
A successful trial shows that taking oral tablet Sunitinib for one year reduces the likelihood of kidney cancer returning for patients following removal of the kidney. The treatment improves disease-free survival and reduces the risk of relapse by 40-50% compared to placebo.
A pooled analysis of 16 prospective multicenter trials found financial difficulties associated with a 35% greater risk of worse global quality-of-life response and a 20% increase in risk of death. Financial burden was present in 26% of patients at baseline, and worsening financial problems during treatment increased mortality risk.
Single-arm trials can provide valuable opportunities for speeding up cancer drug development and approval, particularly in small populations with high unmet medical need. Regulatory guidance is being developed to define evidence requirements for SATs, and initial approvals based on SATs have similar success rates to RCTs.
A phase III trial has met its primary endpoint, demonstrating improved disease-free survival with sunitinib in high-risk renal cell carcinoma patients after nephrectomy. The treatment showed a significantly longer disease-free survival of 6.8 years compared to 5.6 years with placebo.
The ASCEND-5 study showed ceritinib significantly improved progression-free survival compared to chemotherapy in crizotinib-pre-treated patients with non-small-cell lung cancer harbouring an ALK rearrangement. Ceritinib also increased overall response rate, but did not improve overall survival.
In the ASCEND-5 study, ceritinib significantly improved progression-free survival compared to chemotherapy in patients with non-small-cell lung cancer harbouring an ALK rearrangement. The primary endpoint was a median progression-free survival of 5.4 months with ceritinib versus 1.6 months with chemotherapy.
Nintedanib significantly improves median progression-free survival compared to placebo, with disease control improved by 26% compared to 11% in the placebo group. However, overall survival did not differ between the two groups.
A phase I/II trial of dabrafenib found a high response rate in pediatric brain tumors with the BRAF V600 mutation, suggesting potential for targeted therapy. The drug showed significant improvement in tumor shrinkage and overall patient survival.
A study published in Nature Medicine found that the Zika virus can rapidly infect brain and nervous tissues, and is shed in bodily fluids such as semen and urine. The research highlights the need for enhanced clinical vigilance and the rapid development of vaccines and therapies against the virus.
A study found that over 90% of targeted therapy and immunotherapy trials scored poorly on reporting recurrent and late toxicities. Limitations were also seen in presenting adverse events and assessing follow-up intervals.